swainsonine - CISMeF

Preferred Label : swainsonine;

MeSH definition : An indolizidine alkaloid from the plant Swainsona canescens that is a potent alpha-mannosidase inhibitor. Swainsonine also exhibits antimetastatic, antiproliferative, and immunomodulatory activity.;

MeSH hyponym : swainsonine, (8a alpha)-Isomer; swainsonine, (1R-(2 beta,8a alpha))-Isomer; swainsonine, (8 alpha,8a alpha)-Isomer; swainsonine, (8 alpha)-Isomer; swainsonine, (2 beta,8a alpha)-Isomer;

MeSH CAS label : 1,2,8-Indolizinetriol, octahydro-, (1S-(1alpha,2alpha,8beta,8abeta))-;

MeSH Related Number : swainsonine, (8a alpha)-Isomer; swainsonine, (8 alpha)-Isomer; swainsonine, (8 alpha,8a alpha)-Isomer; swainsonine, (1R-(2 beta,8a alpha))-Isomer; swainsonine, (2 beta,8a alpha)-Isomer; 107982-28-5 ((1R-(2 beta,8a alpha))-isomer); 111467-60-8 ((8a alpha)-isomer); 116497-15-5 ((2 beta,8a alpha)-isomer); 116497-16-6 ((8 alpha,8a alpha)-isomer); 72741-87-8 (Swainsonine); 96648-51-0 ((8 alpha)-isomer);

Registry Number MeSH : 72741-87-8;

Related CAS MeSH : 111467-60-8 (Swainsonine, (8a alpha)-Isomer); 96648-51-0 (Swainsonine, (8 alpha)-Isomer); 116497-16-6 (Swainsonine, (8 alpha,8a alpha)-Isomer); 107982-28-5 (Swainsonine, (1R-(2 beta,8a alpha))-Isomer); 116497-15-5 (Swainsonine, (2 beta,8a alpha)-Isomer);

Wikipedia link : https://en.wikipedia.org/wiki/Swainsonine;

Is substance : O;

UNII : RSY4RK37KQ;

InChIKey : FXUAIOOAOAVCGD-WCTZXXKLSA-N;

Details

Origin ID

D017026;

UMLS CUI

C0085535;

Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Automatic exact mappings (from CISMeF team)
- Tridolgosir [NCIt concept]
Pharmacological action(s)
- adjuvants, immunologic [MeSH Descriptor]
- antineoplastic agents, phytogenic [MeSH Descriptor]
- enzyme inhibitors [MeSH Descriptor]
Record concept(s)
- swainsonine [MeSH concept]
- swainsonine, (1R-(2 beta,8a alpha))-Isomer [MeSH concept]
- swainsonine, (2 beta,8a alpha)-Isomer [MeSH concept]
- swainsonine, (8 alpha)-Isomer [MeSH concept]
- swainsonine, (8 alpha,8a alpha)-Isomer [MeSH concept]
- swainsonine, (8a alpha)-Isomer [MeSH concept]
Related MeSH Supplementary Concept(s)
- 1,2-di-epi-swainsonine [MeSH Supplementary Concept]
- 8-epi-swainsonine [MeSH Supplementary Concept]
- swainsonine-human serum albumin conjugate [MeSH Supplementary Concept]
- thioswainsonine [MeSH Supplementary Concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients